155 related articles for article (PubMed ID: 28750592)
1. FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes.
Davidson T; Kedmi M; Avigdor A; Komisar O; Chikman B; Lidar M; Goshen E; Tzila Zwas S; Ben-Haim S
Leuk Lymphoma; 2018 Feb; 59(2):348-356. PubMed ID: 28750592
[TBL] [Abstract][Full Text] [Related]
2. B-cell peripheral neurolymphomatosis: MRI and
DeVries AH; Howe BM; Spinner RJ; Broski SM
Skeletal Radiol; 2019 Jul; 48(7):1043-1050. PubMed ID: 30666391
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of 18F-FDG PET/CT in the detection of neurolymphomatosis.
Zhou WL; Wu HB; Weng CS; Han YJ; Wang M; Huang S; Wang QS
Nucl Med Commun; 2014 Nov; 35(11):1107-11. PubMed ID: 25144562
[TBL] [Abstract][Full Text] [Related]
4. Neurolymphomatosis: MRI and (18) FDG-PET features.
Lim AT; Clucas D; Khoo C; Parameswaran BK; Lau E
J Med Imaging Radiat Oncol; 2016 Feb; 60(1):92-5. PubMed ID: 25974748
[TBL] [Abstract][Full Text] [Related]
5. FDG PET to Diagnose Neurolymphomatosis in a Case of Triple-Hit B-Cell Lymphoma.
Bund C; Heimburger C; Trensz P; Fohrer C; Kremer S; Namer IJ
Clin Nucl Med; 2017 Jun; 42(6):458-460. PubMed ID: 28240665
[TBL] [Abstract][Full Text] [Related]
6.
Tan X; Sun X; Yuan H; He L; Ding C; Jiang L
Hell J Nucl Med; 2022; 25(3):285-296. PubMed ID: 36507885
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases.
Kinoshita H; Yamakado H; Kitano T; Kitamura A; Yamashita H; Miyamoto M; Hitomi T; Okada T; Nakamoto Y; Sawamoto N; Takaori-Kondo A; Takahashi R
J Neurol; 2016 Sep; 263(9):1719-26. PubMed ID: 27286845
[TBL] [Abstract][Full Text] [Related]
8. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
9. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
10. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT in Pediatric Neurolymphomatosis.
de Vaugelade C; de Clermont-Gallerande H; Meyer M; My Duyen Tiphaine A; Benjamin A; Ducassou S; Chateil JF; Fernandez P
Clin Nucl Med; 2017 May; 42(5):e255-e257. PubMed ID: 28288046
[TBL] [Abstract][Full Text] [Related]
12. Neurolymphomatosis: a single-center experience of neuromuscular manifestations, treatments, and outcomes.
Jeong J; Kim SW; Sung DH
J Neurol; 2021 Mar; 268(3):851-859. PubMed ID: 33098033
[TBL] [Abstract][Full Text] [Related]
13. [Neurolymphomatosis due to enteropathy-associated T-cell lymphoma clinically diagnosed by FDG-PET/CT and subsequently confirmed by autopsy].
Uematsu N; Sumi M; Kaiume H; Takeda W; Kirihara T; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Watanabe M; Kobayashi H
Rinsho Ketsueki; 2018; 59(1):69-74. PubMed ID: 29415941
[TBL] [Abstract][Full Text] [Related]
14. High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma.
Matsue K; Hayama BY; Iwama K; Koyama T; Fujiwara H; Yamakura M; Takeuchi M; O'uchi T
Cancer; 2011 Oct; 117(19):4512-21. PubMed ID: 21448935
[TBL] [Abstract][Full Text] [Related]
15. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
16. Fluorothymidine PET/CT in neurolymphomatosis.
Biswal CK; Mittal BR; Shukla J; Vatsa R; Bhattacharya A; Prabhakar S
Clin Nucl Med; 2015 May; 40(5):e290-2. PubMed ID: 25546221
[TBL] [Abstract][Full Text] [Related]
17. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
18. An Extremely Rare Intersection: Neurolymphomatosis in a Patient with Burkitt Lymphoma Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Oner AO; Okuyucu K; Alagoz E; Battal B; Arslan N
World J Nucl Med; 2016 Sep; 15(3):209-11. PubMed ID: 27651745
[TBL] [Abstract][Full Text] [Related]
19. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
